Harborside


InMed Pharmaceuticals Inc.

INM


Canadian symbol: INM
US symbol: INM

Currency in USD

Valuation Measures4

Market Cap (intraday) 21.06M
Enterprise Value 5.94M
Trailing P/E N/A
Forward P/E N/A
PEG Ratio (5 yr expected) N/A
Price/Sales (ttm)N/A
Price/Book (mrq)1.38
Enterprise Value/Revenue N/A
Enterprise Value/EBITDA -0.54

Trading Information

Stock Price History

Beta (5Y Monthly) 1.55
52-Week Change 3-54.63%
S&P500 52-Week Change 322.93%
52 Week High 36.4200
52 Week Low 31.2550
50-Day Moving Average 31.6123
200-Day Moving Average 32.6813

Share Statistics

Avg Vol (3 month) 33.09M
Avg Vol (10 day) 31.32M
Shares Outstanding 514.14M
Implied Shares Outstanding 6N/A
Float 813.76M
% Held by Insiders 10.69%
% Held by Institutions 17.60%
Shares Short (Nov. 14, 2021) 488.49k
Short Ratio (Nov. 14, 2021) 40.1
Short % of Float (Nov. 14, 2021) 40.63%
Short % of Shares Outstanding (Nov. 14, 2021) 40.63%
Shares Short (prior month Oct. 14, 2021) 465.06k

Dividends & Splits

Forward Annual Dividend Rate 4N/A
Forward Annual Dividend Yield 4N/A
Trailing Annual Dividend Rate 3N/A
Trailing Annual Dividend Yield 3N/A
5 Year Average Dividend Yield 4N/A
Payout Ratio 40.00%
Dividend Date 3Jul. 05, 2020
Ex-Dividend Date 4N/A
Last Split Factor 21:33
Last Split Date 3Jul. 05, 2020

Financial Highlights

Fiscal Year

Fiscal Year Ends Jun. 29, 2021
Most Recent Quarter (mrq)Sep. 29, 2021

Profitability

Profit Margin 0.00%
Operating Margin (ttm)0.00%

Management Effectiveness

Return on Assets (ttm)-59.55%
Return on Equity (ttm)-119.13%

Income Statement

Revenue (ttm)N/A
Revenue Per Share (ttm)N/A
Quarterly Revenue Growth (yoy)N/A
Gross Profit (ttm)N/A
EBITDA -11.15M
Net Income Avi to Common (ttm)-11.58M
Diluted EPS (ttm)-1.3740
Quarterly Earnings Growth (yoy)N/A

Balance Sheet

Total Cash (mrq)15.34M
Total Cash Per Share (mrq)1.09
Total Debt (mrq)260.82k
Total Debt/Equity (mrq)1.71
Current Ratio (mrq)8.29
Book Value Per Share (mrq)1.47

Cash Flow Statement

Operating Cash Flow (ttm)-11.07M
Levered Free Cash Flow (ttm)-6.18M

mrq = Most Recent Quarter
ttm = Trailing Twelve Months
yoy = Year Over Year
lfy = Last Fiscal Year
fye = Fiscal Year Ending
fy = Forward Year
Shares outstanding is taken from the most recently filed quarterly or annual report and Market Cap is calculated using shares outstanding.

Fundamentals are updated every day.
Full screen




Cannabis Market and Business News

Real-time cannabis business news from hundreds of sources. Never miss the news that matters the most.




Company News Date
INM
InMed Pharmaceuticals
2 weeks ago
INM
InMed Pharmaceuticals
2 weeks ago
INM
InMed Pharmaceuticals
3 weeks ago
INM
InMed Pharmaceuticals
3 weeks ago
INM
InMed Pharmaceuticals
2 months ago
INM
InMed Pharmaceuticals
2 months ago
INM
InMed Pharmaceuticals
2 months ago
INM
InMed Pharmaceuticals
2 months ago
INM
InMed Pharmaceuticals
2 months ago
INM
InMed Pharmaceuticals
6 months ago
INM
InMed Pharmaceuticals
6 months ago
INM
InMed Pharmaceuticals
7 months ago
INM
InMed Pharmaceuticals
7 months ago
INM
InMed Pharmaceuticals
10 months ago
INM
InMed Pharmaceuticals
10 months ago
INM
InMed Pharmaceuticals
1 year ago
INM
InMed Pharmaceuticals
1 year ago
INM
InMed Pharmaceuticals
1 year ago
INM
InMed Pharmaceuticals
1 year ago
INM
InMed Pharmaceuticals
1 year ago
INM
InMed Pharmaceuticals
1 year ago
INM
InMed Pharmaceuticals
1 year ago
INM
InMed Pharmaceuticals
1 year ago
INM
InMed Pharmaceuticals
1 year ago
INM
InMed Pharmaceuticals
1 year ago
INM
InMed Pharmaceuticals
1 year ago
INM
InMed Pharmaceuticals
1 year ago
INM
InMed Pharmaceuticals
2 years ago
INM
InMed Pharmaceuticals
2 years ago
INM
InMed Pharmaceuticals
2 years ago
INM
InMed Pharmaceuticals
2 years ago
INM
InMed Pharmaceuticals
2 years ago
INM
InMed Pharmaceuticals
2 years ago
INM
InMed Pharmaceuticals
2 years ago
INM
InMed Pharmaceuticals
2 years ago
INM
InMed Pharmaceuticals
2 years ago
INM
InMed Pharmaceuticals
2 years ago
INM
InMed Pharmaceuticals
2 years ago
INM
InMed Pharmaceuticals
2 years ago
INM
InMed Pharmaceuticals
2 years ago
INM
InMed Pharmaceuticals
2 years ago
INM
InMed Pharmaceuticals
2 years ago
INM
InMed Pharmaceuticals
2 years ago
INM
InMed Pharmaceuticals
2 years ago
INM
InMed Pharmaceuticals
2 years ago
INM
InMed Pharmaceuticals
2 years ago

Currency in USD
Earnings EstimateCurrent Qtr. (Dec 2021)Next Qtr. (Mar 2022)Current Year (2022)Next Year (2023)
No. of Analysts2233
Avg. Estimate-0.23-0.21-0.93-0.75
Low Estimate-0.24-0.22-1-0.83
High Estimate-0.23-0.21-0.87-0.69
Year Ago EPSN/AN/A-1.52-0.93
Revenue EstimateCurrent Qtr. (Dec 2021)Next Qtr. (Mar 2022)Current Year (2022)Next Year (2023)
No. of Analysts2233
Avg. Estimate120k420k800k2.5M
Low EstimateN/A250kN/AN/A
High Estimate250k600k1.85M5M
Year Ago SalesN/AN/AN/A800k
Sales Growth (year/est)N/AN/AN/A212.50%
Earnings HistoryInvalid DateInvalid Date2021-06-292021-09-29
EPS Est.N/AN/A-0.34-0.35
EPS ActualN/AN/A-0.41-0.25
DifferenceN/AN/A-0.070.1
Surprise %N/AN/A-20.60%28.60%
EPS TrendCurrent Qtr. (Dec 2021)Next Qtr. (Mar 2022)Current Year (2022)Next Year (2023)
Current Estimate-0.23-0.21-0.93-0.75
7 Days Ago-0.23-0.22-0.96-0.77
30 Days Ago-0.28-0.27-1.1-0.87
60 Days Ago-0.28-0.27-1.1-0.87
90 Days Ago0000
EPS RevisionsCurrent Qtr. (Dec 2021)Next Qtr. (Mar 2022)Current Year (2022)Next Year (2023)
Up Last 7 DaysN/AN/AN/AN/A
Up Last 30 Days1122
Down Last 7 DaysN/AN/AN/AN/A
Down Last 30 DaysN/AN/AN/AN/A
Growth EstimatesINMIndustrySector(s)S&P 500
Current Qtr.N/AN/AN/AN/A
Next Qtr.N/AN/AN/AN/A
Current Year38.80%N/AN/AN/A
Next Year19.40%N/AN/AN/A
Next 5 Years (per annum)N/AN/AN/AN/A
Past 5 Years (per annum)N/AN/AN/AN/A


Insiders transactions are updated every hour.

Major Holders

Currency in USD
Breakdown
0.69%% of Shares Held by All Insider
7.60%% of Shares Held by Institutions
7.65%% of Float Held by Institutions
21Number of Institutions Holding Shares

Top Institutional Holders

HolderSharesDate Reported% OutValue
Armistice Capital, LLC510,000Sep. 29, 20213.61%892,500
Citadel Advisors LLC17,942Sep. 29, 20210.13%31,398
Virtu Financial LLC11,344Sep. 29, 20210.08%19,852
Creative Planning10,841Sep. 29, 20210.08%18,971
UBS Group AG4,861Sep. 29, 20210.03%8,506
PNC Financial Services Group, Inc.1,820Sep. 29, 20210.01%3,185
Advisor Group, Inc.1,185Sep. 29, 20210.01%2,073

Top Mutual Fund Holders

HolderSharesDate Reported% OutValue
Fidelity NASDAQ Composite Index Fund4,383Sep. 29, 20210.03%7,670
Fidelity NASDAQ Composite Index ETF3,060Sep. 29, 20210.02%5,355
Coming Soon

Search SEDAR Filings

Company Name:
Document Type:
Start Date:
End Date:

Press Releases by InMed Pharmaceuticals Inc.


InMed Pharmaceuticals to Participate in Cowen's 4th Annual Cannabis Conference

InMed Pharmaceuticals to Participate in Cowen’s 4th Annual Cannabis Conference

VANCOUVER, British Columbia, Nov. 23, 2021 -- InMed Pharmaceuticals Inc. (“InMed” or the “Company”) (Nasdaq: INM), a leader in the development, manufacturing and commercialization of rare cannabinoids, today announced that InMed’s management team is scheduled to participate in Cowen’s 4th Annual Cannabis Conference to be held virtually on... Read More...
InMed Pharmaceuticals Files PCT Patent Application for Treating Neurodegenerative Disease Using a Rare Cannabinoid

InMed Pharmaceuticals Files PCT Patent Application for Treating Neurodegenerative Disease Using a Rare Cannabinoid

Patent covers novel effects for neurodegenerative diseasesExpands InMed’s patent portfolio with incremental rare cannabinoid VANCOUVER, British Columbia, Nov. 03, 2021 -- InMed Pharmaceuticals Inc. (“InMed” or the “Company”) (Nasdaq: INM), a leader in the manufacturing, development and commercialization of rare cannabinoids, today announ... Read More...
InMed Pharmaceuticals Completes Acquisition of BayMedica Creating a Market Leader in the Manufacturing of Rare Cannabinoids

InMed Pharmaceuticals Completes Acquisition of BayMedica Creating a Market Leader in the Manufacturing of Rare Cannabinoids

VANCOUVER, British Columbia and SOUTH SAN FRANCISCO, Calif., Oct. 13, 2021 -- InMed Pharmaceuticals Inc. (“InMed” or the “Company”) (Nasdaq: INM), a leader in the manufacturing and clinical development of rare cannabinoids, today announced that they have completed the previously announced acquisition of BayMedica Inc. (“BayMedica”), a pri... Read More...
InMed Pharmaceuticals Announces Commencement of Phase 2 Clinical Trial Investigating Cannabinol (CBN), a Rare Cannabinoid, in the Treatment of Epidermolysis Bullosa

InMed Pharmaceuticals Announces Commencement of Phase 2 Clinical Trial Investigating Cannabinol (CBN), a Rare Cannabinoid, in the Treatment of Epidermolysis Bullosa

VANCOUVER, British Columbia, Sept. 30, 2021 -- InMed Pharmaceuticals Inc. (“InMed” or the “Company”) (Nasdaq: INM), a leader in the manufacturing and clinical development of rare cannabinoids, today announced that it has commenced its Phase 2 clinical trial of INM-755 (cannabinol) cream in the treatment of Epidermolysis Bullosa (“EB”). Th... Read More...
InMed Pharmaceuticals Reports Full Year Fiscal 2021 Financial Results and Provides Business Update

InMed Pharmaceuticals Reports Full Year Fiscal 2021 Financial Results and Provides Business Update

VANCOUVER, British Columbia, Sept. 24, 2021 -- InMed Pharmaceuticals Inc. (“InMed” or the “Company”) (Nasdaq: INM), a leader in the manufacturing and clinical development of rare cannabinoids, today reported financial results for the fiscal year ended June 30, 2021. Conference Call & Webcast:Friday, September 24, 2021, at 8:00 AM Paci... Read More...
InMed Pharmaceuticals to Report Full Year Fiscal 2021 Financial Results and Business Update on September 24, 2021

InMed Pharmaceuticals to Report Full Year Fiscal 2021 Financial Results and Business Update on September 24, 2021

VANCOUVER, British Columbia, Sept. 17, 2021 -- InMed Pharmaceuticals Inc. (“InMed” or the “Company”) (Nasdaq: INM), a leader in the manufacturing and clinical development of rare cannabinoids, will report financial results for the fiscal year ended June 30, 2021, on Friday, September 24, 2021. Conference Call & Webcast*:Friday, Septem... Read More...
InMed Pharmaceuticals Signs Definitive Agreement to Acquire BayMedica, a Leading Commercial Manufacturer of Rare Cannabinoids

InMed Pharmaceuticals Signs Definitive Agreement to Acquire BayMedica, a Leading Commercial Manufacturer of Rare Cannabinoids

Establishes leadership position in manufacturing and commercialization of rare cannabinoidsPositions InMed within large and growing consumer health and wellness cannabinoid marketsTransitions InMed into revenue generating company; acquires pipeline with numerous planned product launches VANCOUVER, British Columbia, Sept. 13, 2021 -- InMed... Read More...
InMed Pharmaceuticals to Present at the H.C. Wainwright 23rd Annual Global Investment Conference

InMed Pharmaceuticals to Present at the H.C. Wainwright 23rd Annual Global Investment Conference

VANCOUVER, British Columbia, Sept. 09, 2021 -- InMed Pharmaceuticals Inc. (“InMed” or the “Company”) (Nasdaq: INM), a leader in the manufacturing and clinical development of rare cannabinoids, today announced that Eric. A. Adams, President and CEO of InMed will present at the H.C. Wainwright 23rd Annual Global Investment Conference which ... Read More...
InMed Pharmaceuticals to Present at the H.C. Wainwright Ophthalmology Virtual Conference

InMed Pharmaceuticals to Present at the H.C. Wainwright Ophthalmology Virtual Conference

VANCOUVER, British Columbia, Aug. 12, 2021 -- InMed Pharmaceuticals Inc. (“InMed” or the “Company”) (Nasdaq: INM), a clinical-stage company developing cannabinoid-based pharmaceutical drug candidates as well as manufacturing technologies for pharmaceutical-grade rare cannabinoids, today announced that Eric. A. Adams, President and CEO, an... Read More...
InMed Pharmaceuticals Announces Closing of US$12 Million Private Placement Priced At-the-Market under Nasdaq Rules

InMed Pharmaceuticals Announces Closing of US$12 Million Private Placement Priced At-the-Market under Nasdaq Rules

VANCOUVER, British Columbia, July 02, 2021 -- InMed Pharmaceuticals Inc. (“InMed” or the “Company”) (Nasdaq: INM), a clinical-stage company developing cannabinoid-based pharmaceutical drug candidates as well as manufacturing technologies for pharmaceutical-grade rare cannabinoids, today announced that it has closed the previously announce... Read More...
InMed Pharmaceuticals Announces $12 Million Private Placement Priced At-the-Market under Nasdaq Rules

InMed Pharmaceuticals Announces $12 Million Private Placement Priced At-the-Market under Nasdaq Rules

VANCOUVER, British Columbia, June 29, 2021 -- InMed Pharmaceuticals Inc. (“InMed” or the “Company”) (Nasdaq: INM), a clinical-stage company developing cannabinoid-based pharmaceutical drug candidates as well as manufacturing technologies for pharmaceutical-grade rare cannabinoids, today announced that it has entered into a securities purc... Read More...
InMed Pharmaceuticals Signs Non-binding Letter of Intent to Acquire BayMedica, a Commercial Manufacturer of Rare Cannabinoids

InMed Pharmaceuticals Signs Non-binding Letter of Intent to Acquire BayMedica, a Commercial Manufacturer of Rare Cannabinoids

VANCOUVER, British Columbia, June 29, 2021 -- InMed Pharmaceuticals Inc. (“InMed” or the “Company”) (Nasdaq: INM), a clinical-stage company developing cannabinoid-based pharmaceutical drug candidates as well as manufacturing technologies for pharmaceutical-grade rare cannabinoids, announced that it has entered into a non-binding letter of... Read More...
InMed Pharmaceuticals Increases Cannabinoid Yield to 5 g/L with IntegraSyn™ in Advance of Commercial Scale Production

InMed Pharmaceuticals Increases Cannabinoid Yield to 5 g/L with IntegraSyn™ in Advance of Commercial Scale Production

5 g/L cannabinoid yield significantly exceeds reported industry yieldsSignificantly reduces the overall cost of rare cannabinoid manufacturingContinued advancement to GMP-ready large-scale batch production VANCOUVER, British Columbia, June 17, 2021 -- InMed Pharmaceuticals Inc. (“InMed” or the “Company”) (Nasdaq: INM), a clinical-stage co... Read More...
InMed Pharmaceuticals to Present at the 2021 BIO Digital Conference

InMed Pharmaceuticals to Present at the 2021 BIO Digital Conference

VANCOUVER, British Columbia, June 09, 2021 -- InMed Pharmaceuticals Inc. (“InMed” or the “Company”) (Nasdaq: INM), a clinical-stage company developing cannabinoid-based pharmaceutical drug candidates and leading the clinical development of cannabinol (“CBN”), today announced that Eric. A. Adams, President and CEO of InMed, will present at... Read More...
InMed Pharmaceuticals Reports Third Quarter Fiscal 2021 Financial Results

InMed Pharmaceuticals Reports Third Quarter Fiscal 2021 Financial Results

VANCOUVER, British Columbia, May 13, 2021 -- InMed Pharmaceuticals Inc. (“InMed” or the “Company”) (NASDAQ:INM), a clinical-stage company developing pharmaceutical-based drug candidates and leading the way in the clinical development of cannabinol (“CBN”), today reported financial results for the third quarter of fiscal year 2021 (“3Q21”)... Read More...
InMed Pharmaceuticals to Report Third Quarter Fiscal 2021 Financial Results

InMed Pharmaceuticals to Report Third Quarter Fiscal 2021 Financial Results

VANCOUVER, British Columbia, May 06, 2021 -- InMed Pharmaceuticals Inc. (“InMed” or the “Company”) (NASDAQ:INM; TSX:IN), a clinical-stage company developing pharmaceutical-based drug candidates and leading the way in the clinical development of cannabinol (“CBN”), will report financial results on Thursday, May 13, 2021 for the third quart... Read More...
InMed to Present at Canaccord Genuity's 5th Annual Global Cannabis Conference on May 11th, 2021

InMed to Present at Canaccord Genuity’s 5th Annual Global Cannabis Conference on May 11th, 2021

VANCOUVER, British Columbia, May 04, 2021 -- InMed Pharmaceuticals Inc. (“InMed” or the “Company”) (Nasdaq: INM; TSX:IN), a clinical-stage company developing cannabinoid-based pharmaceutical drug candidates and leading the clinical development of cannabinol (“CBN”), today announced that Eric. A. Adams, President and CEO of InMed, will be ... Read More...
InMed Pharmaceuticals Submits Clinical Trial Applications to Evaluate INM-755 (Cannabinol) Cream in a Phase 2 Trial for Epidermolysis Bullosa

InMed Pharmaceuticals Submits Clinical Trial Applications to Evaluate INM-755 (Cannabinol) Cream in a Phase 2 Trial for Epidermolysis Bullosa

Filings submitted in Austria, Israel, and Serbia for a Phase 2 Clinical Trial with INM-755 creamAdditional submissions slated for France, Germany, Greece, and Italy over the next several days and weeks.Anticipated study on track to begin in 3Q 2021 VANCOUVER, British Columbia, April 28, 2021 -- InMed Pharmaceuticals Inc. (“InMed” or the “... Read More...
InMed Pharmaceuticals Announces Voluntary Delisting from TSX

InMed Pharmaceuticals Announces Voluntary Delisting from TSX

VANCOUVER, British Columbia, April 27, 2021 -- InMed Pharmaceuticals Inc. (“InMed” or the “Company”) (Nasdaq:INM) (TSX:IN), a clinical-stage company developing cannabinoid-based pharmaceutical drug candidates and leading the clinical development of cannabinol (“CBN”), today announced that, based on the strong trading data on the Nasdaq, i... Read More...
InMed Pharmaceuticals Achieves 2g/L Cannabinoid Yield with IntegraSyn™

InMed Pharmaceuticals Achieves 2g/L Cannabinoid Yield with IntegraSyn™

VANCOUVER, British Columbia, April 26, 2021 -- InMed Pharmaceuticals Inc. (“InMed” or the “Company”) (Nasdaq: INM; TSX:IN), a clinical-stage company developing cannabinoid-based pharmaceutical drug candidates and leading the clinical development of cannabinol (“CBN”), today announced that its IntegraSyn™ cannabinoid manufacturing approach... Read More...
InMed to Present at Virtual Conferences in March 2021

InMed to Present at Virtual Conferences in March 2021

VANCOUVER, British Columbia, March 03, 2021 -- InMed Pharmaceuticals Inc. (“InMed” or the “Company”) (Nasdaq: INM; TSX:IN), a clinical-stage company developing cannabinoid-based pharmaceutical drug candidates targeting diseases with high unmet medical need and leading the clinical development of cannabinol (“CBN”), today announced that Er... Read More...
InMed Announces Closing of US$4.5 Million Private Placement

InMed Announces Closing of US$4.5 Million Private Placement

VANCOUVER, BC, Feb. 16, 2021 - InMed Pharmaceuticals Inc. ("InMed") (Nasdaq: INM) (TSX: IN), a clinical-stage pharmaceutical company developing medications targeting diseases with high unmet medical need and leading the clinical development of cannabinol ("CBN"), today announced that it has closed the previously announced private placemen... Read More...
InMed Pharmaceuticals Reports Second Quarter Fiscal 2021 Financial Results

InMed Pharmaceuticals Reports Second Quarter Fiscal 2021 Financial Results

VANCOUVER, BC, Feb. 11, 2021 - InMed Pharmaceuticals Inc. ("InMed") (NASDAQ: INM) (TSX: IN), a clinical-stage pharmaceutical company developing medications targeting diseases with high unmet medical need and leading the way in the clinical development of cannabinol ("CBN"), today reported financial results for the second quarter of fiscal... Read More...
InMed Pharmaceuticals to Report Second Quarter Fiscal 2021 Financial Results

InMed Pharmaceuticals to Report Second Quarter Fiscal 2021 Financial Results

VANCOUVER, BC, Feb. 5, 2021 - InMed Pharmaceuticals Inc. ("InMed") (NASDAQ: INM) (TSX: IN), a clinical-stage pharmaceutical company developing medications targeting diseases with high unmet medical need and leading the way in the clinical development of cannabinol ("CBN"),  will report financial results for the second quarter of fiscal ye... Read More...
InMed Pharmaceuticals to Participate in 2021 Cannabinoid-Derived Pharmaceuticals Industry Review Summit Europe

InMed Pharmaceuticals to Participate in 2021 Cannabinoid-Derived Pharmaceuticals Industry Review Summit Europe

InMed's Michael Woudenberg, Karen Long & Prof. Mauro Maccarrone among Expert Speakers VANCOUVER, BC, Jan. 19, 2021 - InMed Pharmaceuticals Inc. ("InMed") (NASDAQ:INM) (TSX:IN), a clinical-stage pharmaceutical company developing medications targeting diseases with high unmet medical need and leading the clinical development of cannabin... Read More...
InMed Announces Results of Second Phase 1 Clinical Trial of INM-755 CBN Cream in Healthy Subjects

InMed Announces Results of Second Phase 1 Clinical Trial of INM-755 CBN Cream in Healthy Subjects

TSX: IN NASDAQ: INM VANCOUVER, BC, Jan. 8, 2021 - InMed Pharmaceuticals Inc. ("InMed") (NASDAQ: INM) (TSX: IN), a clinical-stage pharmaceutical company developing medications targeting diseases with high unmet medical need and leading the way in the clinical development of cannabinol ("CBN"), today announced top-line results from its 755-... Read More...
InMed Licenses MiDROPS® Delivery Technology from EyeCRO for the Delivery of Therapeutic Cannabinoids

InMed Licenses MiDROPS® Delivery Technology from EyeCRO for the Delivery of Therapeutic Cannabinoids

TSX:IN NASDAQ:INM - Initial application with INM-088 to treat ocular disease - VANCOUVER, BC, Dec. 3, 2020 - InMed Pharmaceuticals Inc. ("InMed") (NASDAQ:INM) (TSX:IN), a clinical-stage pharmaceutical company developing medications targeting diseases with high unmet medical need and leading the way in the clinical development of cannabin... Read More...
InMed Announces Results of Initial Phase 1 Clinical Trial of INM-755 CBN Cream in Healthy Subjects

InMed Announces Results of Initial Phase 1 Clinical Trial of INM-755 CBN Cream in Healthy Subjects

VANCOUVER, BC, Nov. 25, 2020 - InMed Pharmaceuticals Inc. ("InMed") (NASDAQ: INM) (TSX: IN), a clinical-stage pharmaceutical company developing medications targeting diseases with high unmet medical need and leading the way in the clinical development of cannabinol ("CBN"), today announced top-line results from its 755-101-HV Phase 1 clin... Read More...
InMed Pharmaceuticals and BayMedica Announce Collaboration for Manufacturing and Testing of Novel Cannabinoid Therapeutics

InMed Pharmaceuticals and BayMedica Announce Collaboration for Manufacturing and Testing of Novel Cannabinoid Therapeutics

VANCOUVER, BC, Nov. 18, 2020 - InMed Pharmaceuticals Inc. ("InMed") (NASDAQ:INM) (TSX:IN), a clinical-stage pharmaceutical company developing medications targeting diseases with high unmet medical need and leading the way in the clinical development of cannabinol ("CBN"), and BayMedica Inc., a company specializing in the design and manufa... Read More...
InMed Pharmaceuticals Announces the Closing of US$8 Million Public Offering

InMed Pharmaceuticals Announces the Closing of US$8 Million Public Offering

VANCOUVER, BC, Nov. 16, 2020 - InMed Pharmaceuticals Inc. ("InMed") (NASDAQ: INM) (TSX: IN), a clinical-stage pharmaceutical company developing medications targeting diseases with high unmet medical need and leading the clinical development of cannabinol (CBN), today announced that it has closed the previously announced public offering of... Read More...
InMed Pharmaceuticals Reports First Quarter Fiscal 2021 IFRS Financial Results

InMed Pharmaceuticals Reports First Quarter Fiscal 2021 IFRS Financial Results

VANCOUVER, BC, Nov. 13, 2020 - InMed Pharmaceuticals Inc. ("InMed") (NASDAQ: INM) (TSX: IN), a clinical-stage pharmaceutical company developing medications targeting diseases with high unmet medical need and leading the way in the clinical development of cannabinol ("CBN"), in compliance with continuous disclosure obligations in Canada, t... Read More...
InMed Announces Pricing of US$8M Public Offering and Listing on the Nasdaq Capital Market Under the Symbol "INM"

InMed Announces Pricing of US$8M Public Offering and Listing on the Nasdaq Capital Market Under the Symbol “INM”

VANCOUVER, BC, Nov. 12, 2020 - InMed Pharmaceuticals Inc. ("InMed") (NASDAQ: INM) (TSX: IN), a clinical-stage pharmaceutical company developing medications targeting diseases with high unmet medical need and leading the clinical development of cannabinol ("CBN"), today announced that it has priced a public offering of an aggregate of 1,78... Read More...
InMed Reschedules Reporting of First Quarter Financial Results and Business Update to November 13, 2020

InMed Reschedules Reporting of First Quarter Financial Results and Business Update to November 13, 2020

VANCOUVER, BC, Nov. 5, 2020 - InMed Pharmaceuticals Inc. ("InMed") (TSX: IN) (OTCQX: IMLFF), a clinical-stage pharmaceutical company developing medications targeting diseases with high unmet medical need and leading the clinical development of cannabinol ("CBN"), today announced that, due to the regulatory quiet period the Company is in, ... Read More...
InMed Pharmaceuticals to Report First Quarter Fiscal 2021 Financial Results and Business Update on November 6, 2020

InMed Pharmaceuticals to Report First Quarter Fiscal 2021 Financial Results and Business Update on November 6, 2020

TSX:IN OTCQX:IMLFF VANCOUVER, BC, Nov. 4, 2020 - InMed Pharmaceuticals Inc. ("InMed") (TSX: IN) (OTCQX: IMLFF), a clinical stage pharmaceutical company developing medications targeting diseases with high unmet medical need and leading the way in the clinical development of cannabinol (CBN), will report financial results for the first quar... Read More...
InMed Announces Completion of Subject Treatments in Second Phase 1 Clinical Trial of INM-755 CBN Cream in Healthy Subjects

InMed Announces Completion of Subject Treatments in Second Phase 1 Clinical Trial of INM-755 CBN Cream in Healthy Subjects

VANCOUVER, BC, Sept. 24, 2020 - InMed Pharmaceuticals Inc. ("InMed") (TSX: IN) (OTCQX: IMLFF), a clinical-stage pharmaceutical company developing medications targeting diseases with high unmet medical need and leading the way in the clinical development of cannabinol ("CBN"), today announced that all subjects participating in its second P... Read More...
InMed Pharmaceuticals Announces Additional IntegraSyn™ Patent Filing

InMed Pharmaceuticals Announces Additional IntegraSyn™ Patent Filing

TSX:IN OTCQX:IMLFF VANCOUVER, BC, Sept. 22, 2020 - InMed Pharmaceuticals Inc. ("InMed") (TSX:IN) (OTCQX:IMLFF), a clinical-stage pharmaceutical company developing medications targeting diseases with high unmet medical need and leading the way in the clinical development of cannabinol ("CBN"), today announced the filing of a patent applica... Read More...
InMed Pharmaceuticals Reports Full Year Fiscal 2020 Financial Results and Provides Business Update

InMed Pharmaceuticals Reports Full Year Fiscal 2020 Financial Results and Provides Business Update

VANCOUVER, BC, Sept. 8, 2020 - InMed Pharmaceuticals Inc. ("InMed") (TSX:IN;OTCQX:IMLFF), a clinical-stage pharmaceutical company developing medications targeting diseases with high unmet medical need and leading the way in the clinical development of cannabinol ("CBN"), today reported financial results for the fiscal year ended June 30, ... Read More...
InMed Pharmaceuticals to Report Full Year Fiscal 2020 Financial Results and Business Update on September 8, 2020

InMed Pharmaceuticals to Report Full Year Fiscal 2020 Financial Results and Business Update on September 8, 2020

TSX:INOTCQX:IMLFF  VANCOUVER, BC, Sept. 2, 2020 - InMed Pharmaceuticals Inc. ("InMed") (TSX: IN) (OTCQX: IMLFF), a clinical stage pharmaceutical company developing medications targeting diseases with high unmet medical need and leading the way in the clinical development of cannabinol (CBN), will report financial results for the fiscal ye... Read More...
InMed Announces Filing of Registration Statement in Connection with United States Offering, Application to Seek Nasdaq Listing and Planned Share Consolidation

InMed Announces Filing of Registration Statement in Connection with United States Offering, Application to Seek Nasdaq Listing and Planned Share Consolidation

VANCOUVER, BC, June 19, 2020 - InMed Pharmaceuticals Inc. ("InMed") (TSX: IN) (OTCQX: IMLFF), a clinical-stage pharmaceutical company developing medications targeting diseases with high unmet medical need and leading the way in the clinical development of cannabinol ("CBN"), today announced that it has filed a registration statement on Fo... Read More...
InMed Pharmaceuticals Continues to Strengthen Biosynthesis Patent Family

InMed Pharmaceuticals Continues to Strengthen Biosynthesis Patent Family

VANCOUVER, May 19, 2020 - InMed Pharmaceuticals Inc. ("InMed") (TSX:IN;OTCQX:IMLFF), a clinical stage pharmaceutical company developing medications targeting diseases with high unmet medical need and leading the way in the clinical development of cannabinol ("CBN"), today announced the filing of a key Patent Cooperation Treaty ("PCT") pat... Read More...
InMed Pharmaceuticals Reports Third Quarter Fiscal 2020 Financial Results and Provides R&D and Business Update

InMed Pharmaceuticals Reports Third Quarter Fiscal 2020 Financial Results and Provides R&D and Business Update

VANCOUVER, May 14, 2020 - InMed Pharmaceuticals Inc. ("InMed") (TSX: IN; OTCQX: IMLFF), a clinical-stage pharmaceutical company developing medications targeting diseases with high unmet medical need and leading the way in the clinical development of cannabinol ("CBN"), today reported financial results for the third quarter of fiscal year ... Read More...
InMed Pharmaceuticals to Report Third Quarter Fiscal 2020 Financial Results and Business Update on May 14, 2020

InMed Pharmaceuticals to Report Third Quarter Fiscal 2020 Financial Results and Business Update on May 14, 2020

VANCOUVER, May 8, 2020 - InMed Pharmaceuticals Inc. ("InMed") (TSX:IN;OTCQX:IMLFF), a clinical stage pharmaceutical company developing medications targeting diseases with high unmet medical need and leading the way in the clinical development of cannabinol (CBN), will report financial results for the third quarter of fiscal year 2020 endi... Read More...
Coming Soon.

Delayed data (1h)


Share this page